# US 2001/0025033 A1 · Enzyme inactivators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025033 A1
- Document ID: US20010025033A1
- Status: Published application
- Kind: A1
- Application number: 09/841,554
- Filed: 2001-04-23
- Published: 2001-09-27
- Earliest claimed: 1990-07-19
- Assignees: SmithKline Beecham Corporation
- Inventors: Thomas Spector; David J.T. Porter; Saad George Rahim
- Web page: https://patentgrep.com/patent/US20010025033A1

## CPC

- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 7/0812: {comprising a heterocyclic ring}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Use of uracil reductase inactivators such as 5-substituted uracil derivatives for example 5-ethynyluracil to reduce the toxicity of the anti-HIV nucleoside analogue zidovudine.

## Claims

### Claim 1

A pharmaceutical composition comprising uracil substituted in the 5-position by C2-4 alkynyl together with at least one pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is a tablet or a capsule.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the uracil substituted at the 5-position is present at an amount effective to inactivate uracil reductase.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the uracil substituted at the 5-position is present at a dose of 1 to 200 mg.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the uracil substituted at the 5-position is present at a dose of 2 to 50 mg.
